Page last updated: 2024-10-19

melatonin and Alopecia

melatonin has been researched along with Alopecia in 15 studies

Alopecia: Absence of hair from areas where it is normally present.

Research Excerpts

ExcerptRelevanceReference
"The present work aims to formulate nanostructured lipid carriers (NLCs) exhibiting high skin deposition and high inherent antioxidant potential to repurpose the use of melatonin hormone and some antioxidant oils in the treatment of androgenic alopecia (AGA)."9.27Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils. ( Elkheshen, SA; Geneidi, AS; Hatem, S; Moftah, NH; Nasr, M; Ragai, MH, 2018)
"The purpose of the study was to evaluate intermediate adrenal steroid hormones (ISH) in neutered dogs with hair cycle arrest (Alopecia X) during treatment with melatonin, and to see if hair re-growth is associated with sex hormone concentrations within the normal ranges."9.11Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane. ( Frank, LA; Hnilica, KA; Oliver, JW, 2004)
"The strategy in this work was loading Melatonin (MEL), the powerful antioxidant photosensitive molecule, in novel Pickering emulsions (PEs) stabilized by chitosan-dextran sulphate nanoparticles (CS-DS NPs) and enhanced by lecithin, for treatment of androgenic alopecia (AGA)."8.31Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model. ( Abd-Elmonsif, NM; Elshall, AA; Ghoneim, AM; Osman, R; Shaker, DS, 2023)
"The present study aimed to develop vitamin C based nanovesicles (aspasomes) loaded with the antioxidant melatonin, as a novel cosmeceutical to be used for clinical treatment of androgenic alopecia (AGA)."7.88Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal. ( Elkheshen, SA; Geneidi, AS; Hatem, S; Moftah, NH; Nasr, M; Ragai, MH, 2018)
"A total of 11 human studies were identified with evidence of melatonin use in subjects with diagnosed alopecia (2,267 patients; 1,140M)."5.41Melatonin and the Human Hair Follicle. ( Babadjouni, A; Mesinkovska, N; Phong, C; Raffi, J; Reddy, M; Zhang, R, 2023)
"The present work aims to formulate nanostructured lipid carriers (NLCs) exhibiting high skin deposition and high inherent antioxidant potential to repurpose the use of melatonin hormone and some antioxidant oils in the treatment of androgenic alopecia (AGA)."5.27Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils. ( Elkheshen, SA; Geneidi, AS; Hatem, S; Moftah, NH; Nasr, M; Ragai, MH, 2018)
"The purpose of the study was to evaluate intermediate adrenal steroid hormones (ISH) in neutered dogs with hair cycle arrest (Alopecia X) during treatment with melatonin, and to see if hair re-growth is associated with sex hormone concentrations within the normal ranges."5.11Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane. ( Frank, LA; Hnilica, KA; Oliver, JW, 2004)
"The strategy in this work was loading Melatonin (MEL), the powerful antioxidant photosensitive molecule, in novel Pickering emulsions (PEs) stabilized by chitosan-dextran sulphate nanoparticles (CS-DS NPs) and enhanced by lecithin, for treatment of androgenic alopecia (AGA)."4.31Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model. ( Abd-Elmonsif, NM; Elshall, AA; Ghoneim, AM; Osman, R; Shaker, DS, 2023)
"The present study aimed to develop vitamin C based nanovesicles (aspasomes) loaded with the antioxidant melatonin, as a novel cosmeceutical to be used for clinical treatment of androgenic alopecia (AGA)."3.88Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal. ( Elkheshen, SA; Geneidi, AS; Hatem, S; Moftah, NH; Nasr, M; Ragai, MH, 2018)
"Male-pattern baldness (MPB) is a common and highly heritable trait characterized by androgen-dependent, progressive hair loss from the scalp."2.55Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness. ( Anhalt, T; Becker, T; Chew, EG; Dedoussis, G; Del Rosario, RC; Deloukas, P; Drichel, D; Fier, HL; Galesloot, TE; Hecker, J; Heilmann-Heimbach, S; Heng, XT; Herold, C; Hillmer, AM; Hinds, DA; Hochfeld, LM; Javed, A; Kanoni, S; Kiemeney, LA; Kutalik, Z; Li, R; Martin, NG; Moebus, S; Nöthen, MM; Nothnagel, M; Nyholt, DR; Papanikolaou, G; Paus, R; Pechlivanis, S; Philpott, MP; Prabhakar, S; Richards, JB; Rueedi, R; Spector, TD; Vollenweider, P; Waeber, G, 2017)

Research

Studies (15)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's7 (46.67)29.6817
2010's4 (26.67)24.3611
2020's4 (26.67)2.80

Authors

AuthorsStudies
Verschuuren, MUMY1
Schlotter, YM1
van Geijlswijk, IM1
van der Lugt, JJ1
Gehring, R1
Babadjouni, A1
Reddy, M1
Zhang, R1
Raffi, J1
Phong, C1
Mesinkovska, N1
Elshall, AA1
Ghoneim, AM1
Abd-Elmonsif, NM1
Osman, R1
Shaker, DS1
Karabulut, İY1
Gokcay, H1
Belli, H1
Hatem, S2
Nasr, M2
Moftah, NH2
Ragai, MH2
Geneidi, AS2
Elkheshen, SA2
Famenini, S1
Goh, C1
Heilmann-Heimbach, S1
Herold, C1
Hochfeld, LM1
Hillmer, AM1
Nyholt, DR1
Hecker, J1
Javed, A1
Chew, EG1
Pechlivanis, S1
Drichel, D1
Heng, XT1
Del Rosario, RC1
Fier, HL1
Paus, R1
Rueedi, R1
Galesloot, TE1
Moebus, S1
Anhalt, T1
Prabhakar, S1
Li, R1
Kanoni, S1
Papanikolaou, G1
Kutalik, Z1
Deloukas, P1
Philpott, MP1
Waeber, G1
Spector, TD1
Vollenweider, P1
Kiemeney, LA1
Dedoussis, G1
Richards, JB1
Nothnagel, M1
Martin, NG1
Becker, T1
Hinds, DA1
Nöthen, MM1
Perego, R1
Proverbio, D1
Roccabianca, P1
Spada, E1
Fischer, TW1
Burmeister, G1
Schmidt, HW1
Elsner, P1
Peres, MF1
Zukerman, E1
da Cunha Tanuri, F1
Moreira, FR1
Cipolla-Neto, J1
Frank, LA2
Hnilica, KA1
Oliver, JW1
Sladden, MJ1
Hutchinson, PE1
Diaz, SF1
Torres, SM1
Nogueira, SA1
Gilbert, S1
Jessen, CR1
Donnell, RL1
Kania, SA1

Clinical Trials (3)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches[NCT00391755]Phase 44 participants (Actual)Interventional2006-10-31Terminated (stopped due to Failure to recruit necessary number of patients.)
Melatonin for Migraine Prevention (The MMP-study): A Randomized, Double-blind, Cross-over, Placebo-controlled Study of Melatonin in Prophylactic Treatment of Migraine[NCT00849511]Phase 248 participants (Actual)Interventional2009-02-28Completed
"Melatonin for Migraine Prevention in Adolescents: A Pilot Remote Trial: The BRAiN-M Study"[NCT02344316]Phase 231 participants (Actual)Interventional2015-05-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Headache Diary Compliance Rate

Number of participants that had ≥85% headache diary compliance during weeks 12-16 of the study. (NCT02344316)
Timeframe: Weeks 12-16 of the study

InterventionParticipants (Count of Participants)
Melatonin11
Placebo10

Medication Adherence as Measured by Number of Openings Per Participant

eCAP tack caps will be used to measure medication adherence and the number of openings will be recorded per participant. (NCT02344316)
Timeframe: "during the At Home Active Study Period or Weeks 5-16"

InterventionMean Number of Openings (Mean)
Melatonin39
Placebo60

Number of Migraine/Migrainous Days Per 28 Day Period

Number of Migraine/Migrainous Days Per 28 Day Period in melatonin group and placebo group as measured using an online/mobile device headache diary. (NCT02344316)
Timeframe: final 4 weeks of treatment

Interventiondays (Mean)
Melatonin3.6
Placebo4.9

Number of Minutes to Sleep Onset

Number of minutes to sleep onset as measured by a FitBit. (NCT02344316)
Timeframe: 16 weeks

Interventionminutes (Mean)
Melatonin15.2
Placebo17.2

Reviews

2 reviews available for melatonin and Alopecia

ArticleYear
Melatonin and the Human Hair Follicle.
    Journal of drugs in dermatology : JDD, 2023, Mar-01, Volume: 22, Issue:3

    Topics: Alopecia; Hair; Hair Follicle; Humans; Male; Melatonin; Scalp

2023
Meta-analysis identifies novel risk loci and yields systematic insights into the biology of male-pattern baldness.
    Nature communications, 2017, 03-08, Volume: 8

    Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adipogenesis; Alopecia; Case-Control Studies; Fibroblast Grow

2017

Trials

5 trials available for melatonin and Alopecia

ArticleYear
The efficacy of subcutaneous slow-release melatonin implants in the prevention of canine flank alopecia recurrence is uncertain: A double-blind, randomized, placebo-controlled study.
    Veterinary dermatology, 2022, Volume: 33, Issue:6

    Topics: Alopecia; Animals; Dog Diseases; Dogs; Double-Blind Method; Melatonin; Skin

2022
Clinical cosmeceutical repurposing of melatonin in androgenic alopecia using nanostructured lipid carriers prepared with antioxidant oils.
    Expert opinion on drug delivery, 2018, Volume: 15, Issue:10

    Topics: Alopecia; Antioxidants; Cosmeceuticals; Drug Carriers; Drug Repositioning; Humans; Lipids; Melatonin

2018
Melatonin increases anagen hair rate in women with androgenetic alopecia or diffuse alopecia: results of a pilot randomized controlled trial.
    The British journal of dermatology, 2004, Volume: 150, Issue:2

    Topics: Administration, Topical; Adult; Aged; Alopecia; Double-Blind Method; Female; Hair; Humans; Melatonin

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Melatonin, 3 mg, is effective for migraine prevention.
    Neurology, 2004, Aug-24, Volume: 63, Issue:4

    Topics: Adult; Alopecia; Analgesics; Disorders of Excessive Somnolence; Female; Humans; Libido; Male; Melato

2004
Adrenal steroid hormone concentrations in dogs with hair cycle arrest (Alopecia X) before and during treatment with melatonin and mitotane.
    Veterinary dermatology, 2004, Volume: 15, Issue:5

    Topics: Administration, Oral; Adrenal Cortex Hormones; Adrenocorticotropic Hormone; Alopecia; Androstenedion

2004

Other Studies

8 other studies available for melatonin and Alopecia

ArticleYear
Boosting hair growth through follicular delivery of Melatonin through lecithin-enhanced Pickering emulsion stabilized by chitosan-dextran nanoparticles in testosterone induced androgenic alopecia rat model.
    International journal of pharmaceutics, 2023, May-25, Volume: 639

    Topics: Alopecia; Animals; Antioxidants; Chitosan; Dextrans; Emulsions; Hair; Lecithins; Melatonin; Minoxidi

2023
Hair Loss Associated with Escitalopram: Do SSRIs Affect Melatonin at the Hair Follicle?
    Psychiatria Danubina, 2021,Summer, Volume: 33, Issue:2

    Topics: Alopecia; Citalopram; Hair Follicle; Humans; Melatonin; Selective Serotonin Reuptake Inhibitors

2021
Melatonin vitamin C-based nanovesicles for treatment of androgenic alopecia: Design, characterization and clinical appraisal.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2018, Sep-15, Volume: 122

    Topics: Adolescent; Adult; Alopecia; Animals; Antioxidants; Ascorbic Acid; Drug Carriers; Drug Liberation; H

2018
Evidence for supplemental treatments in androgenetic alopecia.
    Journal of drugs in dermatology : JDD, 2014, Volume: 13, Issue:7

    Topics: Alopecia; Biological Products; Biotin; Caffeine; Female; Humans; Male; Melatonin; Zinc

2014
Color dilution alopecia in a blue Doberman pinscher crossbreed.
    The Canadian veterinary journal = La revue veterinaire canadienne, 2009, Volume: 50, Issue:5

    Topics: Administration, Oral; Alopecia; Animals; Antioxidants; Dog Diseases; Dogs; Hair; Hair Color; Male; M

2009
Is melatonin useful in alopecia: critical appraisal of a randomized trial?
    The British journal of dermatology, 2005, Volume: 153, Issue:4

    Topics: Alopecia; Female; Humans; Melatonin; Randomized Controlled Trials as Topic; Research Design; Treatme

2005
The impact of body site, topical melatonin and brushing on hair regrowth after clipping normal Siberian Husky dogs.
    Veterinary dermatology, 2006, Volume: 17, Issue:1

    Topics: Adjuvants, Immunologic; Administration, Topical; Alopecia; Animals; Dog Diseases; Dogs; Hair; Hair F

2006
Oestrogen receptor evaluation in Pomeranian dogs with hair cycle arrest (alopecia X) on melatonin supplementation.
    Veterinary dermatology, 2006, Volume: 17, Issue:4

    Topics: Alopecia; Animals; Dietary Supplements; Dog Diseases; Dogs; Female; Hair Follicle; Immunohistochemis

2006